Dyne Therapeutics (DYN) Capital Expenditures (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Capital Expenditures data on file, last reported at $221000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 77.47% year-over-year to $221000.0 in Q1 2026; TTM through Mar 2026 was $18.0 million, a 1789.94% increase from a year earlier, with the FY2025 full-year figure at $18.8 million, changed N/A from the prior year.
• Capital Expenditures for Q1 2026 stood at $221000.0, down from $17.7 million in the prior quarter.
• Over the last five years, Capital Expenditures for DYN reached as high as $17.7 million in Q3 2025 and fell as low as -$1.7 million in Q3 2022.
• Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $153000.0 in 2022.
• Across the five-year window, Capital Expenditures slumped 861.18% in 2023 and surged 6915.42% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $85000.0 in 2022, then slumped by 861.18% to -$647000.0 in 2023, then slumped by 101.08% to -$1.3 million in 2024, then jumped by 1464.26% to $17.7 million in 2025, then sank by 98.75% to $221000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $221000.0 in Q1 2026, $17.7 million in Q3 2025, and $60000.0 in Q2 2025.